Answers are grounded in this paper and cite their sources.
Phase Ib trial evaluates safety and efficacy of filgotinib in idiopathic multicentric Castleman disease, suggesting positive outcomes.
Objective To evaluate the long-term safety and exploratory efficacy of filgotinib, a JAK1-preferential inhibitor, in patients with idiopathic multicentric Castleman disease (iMCD) over 52 weeks in a small, single-arm extension study. Methods This Phase Ib single-arm extension study enrolled five patients with iMCD who completed an initial 8 weeks' treatment with filgotinib. Patients received filgotinib 200 mg once daily for an additional 44 weeks (total 52 weeks). The primary endpoints assessed the comprehensive safety parameters. The secondary endpoints were efficacy. Results All five patients completed the full 52-week treatment period without permanent discontinuation. No serious adverse events or deaths were observed. All adverse events were mild-to-moderate (Grade 1-2), with upper respiratory infections in 4 patients and headache in 3 of 5 patients. Herpes zoster occurred in one patient. At week 52, three of five patients had ≥1-point CHAP score reduction (one additional patient compared with week 8). Median changes from baseline included: CRP -1.85 mg/dL, hemoglobin +0.50 g/dL, albumin +0.30 g/dL, and ECOG-PS 0 points. Conclusion Filgotinib was well-tolerated over 52 weeks with no serious adverse events reported. Numerical changes in disease activity markers were observed over time, providing preliminary support for the therapeutic concept of JAK inhibition in iMCD.
No takes yet. Share an insight, caveat, or question.
Fukui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: